QIAGEN N.V.
In the published model solve dated 2026-Q2, anchored at $41.91, QIAGEN N.V. (QGEN) is priced for +8.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
QIAGEN is a mature molecular-testing company, not a growth story, and the price should be read that way. At $36.96 the market pays roughly 19 times company-wide operating income, which implies operating profit compounding only about 4% a year for five years. That is within what a steady diagnostics franchise can deliver; the demand is on durability, not pace. The methods split by family. Relative-multiple methods reach the price (sector P/E value near $45, EV/EBITDA near $44, price-to-sales nea
Is QGEN overvalued? See what's priced in →
332 institutional managers reported holding QGEN in 13F filings for the quarter ended 2026-03-31. Together they hold about 57% of the company; the top 10 hold 29%. 93 opened new positions that quarter. Held by Wellington Management, Vanguard Group, T. Rowe Price, among others. On the short side, 7.6M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
QGEN has cut its share count 4.7% over the past five years, spending $672.17M on repurchases. It pays a dividend, and has for 1 year running; the current rate is $0.25 a share annually. Cash returned over the past three years: $54.24M in dividends and $572.18M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.